Drug intelligence / Profile preview

JMJT-DB01

Development stage: Preclinical
Lead developer: Jianming Pharmaceutical Group

Overview

JMJT-DB01 is an investigational drug candidate currently in the preclinical stage of development by Jianming Pharmaceutical Group (Wuhan Jianming Pharmaceutical). It is being developed for the treatment of anemia. As of early 2024, the company has not publicly disclosed the specific molecular target, mechanism of action, or the modality (such as small molecule or biologic) of the compound. The program is part of Jianming's research and development pipeline, which includes various candidates for neurology, respiratory health, and hematological conditions.

Beyond the preview

Go deeper on JMJT-DB01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMJT-DB01.

Explore the full profile